Delivering genes with human immunodeficiency virus-derived vehicles: still state-of-the-art after 25 years.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing the history, biology, and clinical applications of HIV-derived lentiviral vectors without systematic review methodology or original empirical data.
PubMed 36209077 · doi:10.1186/s12929-022-00865-4
What was done
This narrative review summarizes the 25-year history, technological evolution, and applications of human immunodeficiency virus (HIV)-derived lentiviral vectors. The authors review their use in ex vivo gene transfer to hematopoietic stem cells, chimeric antigen receptor (CAR) T-cell production, in vivo gene delivery, basic research tools such as CRISPR genome editing carrier systems, and emerging applications in packaging and delivering foreign proteins.
What was found
The abstract provides a descriptive overview of the vector platform and reports no quantitative outcome data, effect estimates, or statistical comparisons.
Why it matters
It contextualizes the ongoing clinical and laboratory importance of HIV-derived vector systems, summarizing how engineering advancements have transitioned lentiviral vectors from early-stage experimental tools into standard platforms for cell and gene therapy.
Limits
The abstract describes a broad, non-systematic narrative overview with no specific search criteria, study selection parameters, quantitative data synthesis, or primary experimental findings.
Cited by
- supports Lentiviral vectors used to deliver genetic material in CAR-T cell therapies are engineered from modified human immunodeficiency virus (HIV).